Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)

CompletedOBSERVATIONAL

Enrollment

552

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

July 17, 2021

Study Completion Date

January 11, 2022

Conditions

Heart Failure

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

As prescribed by the treating physician

Trial Locations (1)

Many Locations, Multiple Locations